The plasma kallikrein inhibitor Berotralstat, which prevents tissue edema elicited by BK during acute episodes of HAE-C1INH, has been approved for prophylaxis to prevent attacks of HAE-C1INH in adults and adolescent patients aged 12 years or older. This evidence concerns the gene KLK4 and hereditary angioedema.